var data={"title":"Perflutren protein type A: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Perflutren protein type A: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/229235?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=perflutren-protein-type-a-patient-drug-information\" class=\"drug drug_patient\">see &quot;Perflutren protein type A: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709205\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Serious cardiopulmonary reactions: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration. Most serious reactions occur within 30 minutes of administration. Assess all patients for the presence of any condition that precludes administration. Always have resuscitation equipment and trained personnel readily available.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3033664\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Optison</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3033667\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Diagnostic Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3034064\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;\">\n      <b>Opacification of left ventricle:</b> IV:  0.5 mL via peripheral vein; flush with D<sub>5</sub>W or NS following dose; may repeat in increments of 0.5 mL up to 5 mL cumulatively in 10 minutes (maximum total dose: 8.7 mL in any one patient study).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3034065\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22370165\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22370166\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3034070\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, suspension [preservative free]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Optison: Perflutren 0.11-0.33 mg and protein-type A microspheres 5-8 x 10<sup>8</sup> per mL (3 mL) [contains human albumin 10 mg/mL]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3033665\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3034066\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: For IV use only; do not administer intra-arterially. While allowing the vial to come to room temperature, invert and gently rotate to resuspend the microspheres; solution should appear opaque and milky-white. Do <b>not</b> use if solution is clear. Vent vial with a sterile vent spike or 18-gauge needle. Do <b>not </b>inject air into vial. Within 1 minute of resuspension, remove dose from the vial and inject using a &ge;20-gauge angiocatheter into a peripheral vein at a rate &le;1 mL/second. Flush line with D<sub>5</sub>W or NS immediately after injection. Repeat resuspension prior to injection if more than 1 minute elapses.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3033668\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Opacification of left ventricle:</b> Opacification of left ventricle and improvement of delineation of the left ventricular endocardial borders in patients with suboptimal echocardiograms</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3033677\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Flushing (4%), chest pain (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (5%), dizziness (3%), chills (&le;1%), fatigue (&le;1%), malaise (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (&le;4%), vomiting (&le;4%), dysgeusia (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Discomfort at injection site (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea (1%), flu-like symptoms (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylactoid reaction, angioedema, arthralgia, atrial fibrillation, back pain, blurred vision, body pain, bradycardia, bronchospasm, burning sensation of eyes, cough, edema (localized edema, mouth edema, palatal edema, peripheral edema, pharyngeal edema), eosinophilia, erythema, eye irritation, hypersensitivity reaction, hypertension, hypoesthesia, hypotension, hypoxia, irritability, local discoloration (at injection site), loss of consciousness, myalgia, oxygen desaturation (due to coughing), palpitations, paresthesia, photophobia, pruritus, respiratory distress, seizure, shock, skin rash, skin sclerosis, stridor, supraventricular cardiac arrhythmia, supraventricular tachycardia, swelling (facial swelling, swelling of eye, swelling of lips, swollen tongue, upper airway swelling), syncope, tachycardia, tinnitus, tremor, urticaria, ventricular fibrillation, ventricular premature contractions, ventricular tachycardia, wheezing, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3033673\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to perflutren or any component of the formulation, blood, blood products, or albumin</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3033674\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid reactions: Serious anaphylactoid reactions (eg, shock, hypersensitivity, bronchospasm, throat tightness, angioedema, edema [oropharyngeal, peripheral, and localized], swelling [face, eye, lip, tongue, upper airway], facial hypoesthesia, rash, urticaria, pruritus, flushing, and erythema) have been reported in patients with no prior exposure. Monitor for signs and symptoms of anaphylactoid reactions. Equipment for resuscitation and trained personnel should be readily available.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Serious cardiopulmonary reactions: <b>[US Boxed Warning]: Serious cardiopulmonary reactions (some fatal) have occurred uncommonly during or within 30 minutes following administration. Assess all patients for the presence of any condition that precludes administration. Equipment for resuscitation and trained personnel </b><b>experienced in handling medical emergencies should always be immediately available<b>.</b></b> Risk may be increased in patients with unstable cardiopulmonary conditions (eg, acute MI, acute coronary artery syndromes, worsening or unstable heart failure, serious ventricular arrhythmias). However, multiple retrospective and prospective studies involving the use of perflutren-based ultrasound contrast agents have suggested they may be safely used in patients with significant cardiopulmonary disease (ie, acute coronary syndromes, heart failure, COPD, pulmonary hypertension) or critical illness (Dolan 2009; Kurt 2009; Kusnetzky 2008; Main 2008; Main 2014; Nucifora 2008; Wei 2008; Wei 2012; Weiss 2012; Wever-Pinzon 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ventricular arrhythmias: High ultrasound mechanical indices with or without end-systolic triggering may cause ventricular arrhythmias. Use is not recommended at mechanical indices &gt;0.8.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiac shunts: Assess patients for embolic phenomena following administration; microspheres can bypass filtering of the lung and enter the arterial circulation in patients with a cardiac shunt. Patients with small degrees of right-to-left shunting through patent foramen ovales (those that result in transient appearance of saline contrast in the left atrium or ventricle and do not fill the left atrial or LV cavity) are not considered at an increased risk for microvascular occlusion with perflutren-based ultrasound contrast agents (ASE [Porter 2014]; Kalra 2014; Muskula 2017; Parker 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Albumin: Product contains albumin; may carry a remote risk of virus transmission or hypersensitivity reaction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: For IV administration; do not administer by intra-arterial injection.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299853\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6222246\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10335&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3033670\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20617653\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if perflutren protein type A is excreted in breast milk. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of infant exposure, the benefits of breast-feeding to the infant, and benefits of treatment to the mother</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3034069\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Cardiopulmonary reactions (rare); signs and symptoms of anaphylactoid reactions (rare). Monitor patient as appropriate based upon patient clinical disposition; specific monitoring parameters based upon perflutren lipid microspheres administration are not necessary (Muskula 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3033996\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Perflutren is a stable gas that provides an echogenic contrast effect in the blood and allows for improved delineation of the left ventricular endocardial border.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3033998\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Contrast enhancement: Dose dependent: 1 minute (0.2 mL) to 5 minutes (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Perflutren: Not metabolized</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 1.3 &plusmn; 0.69 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Perflutren: Lungs</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27000891\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Optison (AT, CY, CZ, DE, DK, GB, GR, HR, HU, IS, IT, LT, MT, NL, NO, PL, PT, RO, SE, SK, TR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Dolan MS, Gala SS, Dodla S, et al. Safety and efficacy of commercially available ultrasound contrast agents for rest and stress echocardiography a multicenter experience. <i>J Am Coll Cardiol.</i> 2009;53(1):32-38. doi: 10.1016/j.jacc.2008.08.066.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/perflutren-protein-type-a-drug-information/abstract-text/19118722/pubmed\" target=\"_blank\" id=\"19118722\">19118722</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kalra A, Shroff GR, Erlien D, et al. Perflutren-based echocardiographic contrast in patients with right-to-left intracardiac shunts. <i>JACC Cardiovasc Imaging.</i> 2014;7(2):206-207. doi: 10.1016/j.jcmg.2013.11.003.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/perflutren-protein-type-a-drug-information/abstract-text/24524748/pubmed\" target=\"_blank\" id=\"24524748\">24524748</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kurt M, Shaikh KA, Peterson L, et al. Impact of contrast echocardiography on evaluation of ventricular function and clinical management in a large prospective cohort. <i>J Am Coll Cardiol.</i> 2009;53(9):802-810. doi: 10.1016/j.jacc.2009.01.005.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/perflutren-protein-type-a-drug-information/abstract-text/19245974/pubmed\" target=\"_blank\" id=\"19245974\">19245974</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kusnetzky LL, Khalid A, Khumri TM, et al. Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent: results in 18,671 consecutive studies. <i>J Am Coll Cardiol.</i> 2008;51(17):1704-1706. doi: 10.1016/j.jacc.2008.03.006.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/perflutren-protein-type-a-drug-information/abstract-text/18436124/pubmed\" target=\"_blank\" id=\"18436124\">18436124</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Main ML, Ryan AC, Davis TE, et al. Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent (multicenter registry results in 4,300,966 consecutive patients). <i>Am J Cardiol.</i> 2008;102(12):1742-1746. doi: 10.1016/j.amjcard.2008.08.019.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/perflutren-protein-type-a-drug-information/abstract-text/19064035/pubmed\" target=\"_blank\" id=\"19064035\">19064035</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Main ML, Hibberd MG, Ryan A, et al. Acute mortality in critically ill patients undergoing echocardiography with or without an ultrasound contrast agent. <i>JACC Cardiovasc Imaging.</i> 2014;7(1):40-48. doi: 10.1016/j.jcmg.2013.08.012.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/perflutren-protein-type-a-drug-information/abstract-text/24290568/pubmed\" target=\"_blank\" id=\"24290568\">24290568</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Muskula PR, Main ML. Safety with echocardiographic contrast agents. <i>Circ Cardiovascular Imaging.</i> 2017;10(4). pii: e005459. doi: 10.1161/CIRCIMAGING.116.005459.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/perflutren-protein-type-a-drug-information/abstract-text/28377467/pubmed\" target=\"_blank\" id=\"28377467\">28377467</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nucifora G, Marsan NA, Siebelink HM, et al. Safety of contrast-enhanced echocardiography within 24 h after acute myocardial infarction. <i>Eur J Echocardiogr.</i> 2008;9(6):816-818. doi: 10.1093/ejechocard/jen167.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/perflutren-protein-type-a-drug-information/abstract-text/18635517/pubmed\" target=\"_blank\" id=\"18635517\">18635517</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Optison (perflutren protein type A microspheres) [prescribing information]. Marlborough, MA: GE Healthcare; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parker JM, Weller MW, Feinstein LM, et al. Safety of ultrasound contrast agents in patients with known or suspected cardiac shunts.<i> Am J Cardiol.</i> 2013;112(7):1039-1045. doi: 10.1016/j.amjcard.2013.05.042.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/perflutren-protein-type-a-drug-information/abstract-text/23816393/pubmed\" target=\"_blank\" id=\"23816393\">23816393</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Porter TR, Abdelmoneim S, Belcik JT, et al. Guidelines for the cardiac sonographer in the performance of contrast echocardiography: a focused update from the American Society of Echocardiography.<i> J Am Soc Echocardiogr.</i> 2014;27(8):797-810. doi: 10.1016/j.echo.2014.05.011.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/perflutren-protein-type-a-drug-information/abstract-text/25085408/pubmed\" target=\"_blank\" id=\"25085408\">25085408</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wei K, Mulvagh SL, Carson L, et al. The safety of deFinity and Optison for ultrasound image enhancement: a retrospective analysis of 78,383 administered contrast doses. <i>J Am Soc Echocardiogr.</i> 2008;21(11):1202-1206. doi: 10.1016/j.echo.2008.07.019.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/perflutren-protein-type-a-drug-information/abstract-text/18848430/pubmed\" target=\"_blank\" id=\"18848430\">18848430</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wei K, Main ML, Lang RM, et al. The effect of Definity on systemic and pulmonary hemodynamics in patients. <i>J Am Soc Echocardiogr.</i> 2012;25(5):584-588. doi: 10.1016/j.echo.2012.01.019.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/perflutren-protein-type-a-drug-information/abstract-text/22365709/pubmed\" target=\"_blank\" id=\"22365709\">22365709</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weiss RJ, Ahmad M, Villanueva F, et al. CaRES (Contrast Echocardiography Registry for Safety Surveillance): a prospective multicenter study to evaluate the safety of the ultrasound contrast agent definity in clinical practice. <i>J Am Soc Echocardiogr.</i> 2012;25(7):790-795. doi: 10.1016/j.echo.2012.04.002.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/perflutren-protein-type-a-drug-information/abstract-text/22560734/pubmed\" target=\"_blank\" id=\"22560734\">22560734</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wever-Pinzon O, Suma V, Ahuja A, et al. Safety of echocardiographic contrast in hospitalized patients with pulmonary hypertension: a multi-center study. <i>Eur Heart J Cardiovasc Imaging.</i> 2012;13(10):857-862. doi: 10.1093/ehjci/jes057.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/perflutren-protein-type-a-drug-information/abstract-text/22427401/pubmed\" target=\"_blank\" id=\"22427401\">22427401</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10335 Version 62.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709205\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F3033664\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F3033667\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F3034064\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F3034065\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F22370165\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22370166\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F3034070\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F3033665\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F3034066\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F3033668\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F3033677\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F3033673\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F3033674\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299853\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6222246\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F3033670\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20617653\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F3034069\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F3033996\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F3033998\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F27000891\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10335|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=perflutren-protein-type-a-patient-drug-information\" class=\"drug drug_patient\">Perflutren protein type A: Patient drug information</a></li></ul></div></div>","javascript":null}